Recentin misses glioblastoma endpoint

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Recentin cediranib with and without lomustine chemotherapy missed the primary endpoint of significantly improving progression-free survival (PFS) vs. lomustine alone in the Phase III REGAL trial to treat recurrent glioblastoma. Based on the results, AstraZeneca said it will not pursue further development of Recentin in the indication. The double-blind, international trial enrolled about 300 patients. Recentin is a tyrosine kinase inhibitor of VEGF receptors 1, 2 and 3.

In May, AstraZeneca said that based on the results of the HORIZON II and III trials, it did not intend to submit regulatory applications for Recentin to treat first-line metastatic colorectal cancer (mCRC). The pharma said it is continuing to evaluate whether Recentin may have utility in other tumor types. ...